The Primary Care Dermatology Society Logo
THE LEADING DERMATOLOGICAL SOCIETY FOR GPS PCDS on Twitter follow @PCDSUK Contact Us
Website author – Dr Tim Cunliffe (read more)
  • PCDS home
  • About the PCDS
  • Dermatology dictionary
  • Dermatology: the basics
  • Diagnostic tables
  • Dermoscopy
  • Investigations
  • A-Z of clinical guidance
    • A-Z list
  • Self-examination of moles
  • Leg dressings and other bandaging techniques
  • Skin surgery and cryosurgery
  • Other guidelines
  • Quality of Life Measures
  • Research - keep up to date
  • GPwSI & service development
  • PCDS educational events
  • Diplomas and other educational programmes
  • Resources - websites and books
  • Latest news and bulletins
  • Image library
  • Patient information leaflets
  • Patient support groups
  • Fundraising - the BSF
  • Ethical dermatology
  • PCDS website poster
  • Affiliated societies
  • Acknowledgements

Necrolytic migratory erythema

Created: 12th June 2016   |   Last Updated: 20th June 2016

Introduction

Necrolytic migratory erythema (NME) is, in most cases, associated with a glucagonoma, which is a slow growing malignant tumour predominantly arising in the α‐cells of the pancreas. The triad of an unusual dermatosis, recent‐onset diabetes and weight loss should trigger consideration of NME, although cutaneous manifestations may precede the diagnosis of glucagonoma by several years.

This chapter is set out as follows:

  • Aetiology
  • History
  • Clinical findings
  • Images
  • Investigations
  • Management

Aetiology

  • Most glucagonoma's arise in the α‐cells of the pancreas, and can be part of a multiple endocrine neoplasia syndrome
  • Rarely, glucagon‐secreting tumours can arise at other sites eg bronchial or naso‐pharyngeal
  • Similar symptoms can arise in the absence of a glucagon‐secreting tumour (Pseudoglucagonoma syndrome), secondary to pancreatic insufficiency, coeliac disease and intestinal malabsorption syndromes, inflammatory bowel disease, cirrhosis, non‐pancreatic malignancies and the Myelodysplastic syndrome

History

  • A glucagonoma is very rare and usually affects adults over the age of 50
  • There is often a delay in diagnosis as patients usually present with nonspecific complaints, such as weight loss, diabetes, diarrhoea, and stomatitis, additionally early cutaneous lesions may be mild and histology non-diagnostic
  • Over time skin lesions become more uncomfortable
  • Other features may include venous thrombosis, neurological and psychiatric symptoms

Clinical findings

  • Distribution
    • NME may involve any site but it most often affects the perineum, buttocks, groin, lower abdomen, and lower extremities, areas subject to greater pressure and friction
       
  • Morphology
    • The lesions wax and wane in a cycle of about 10 days, beginning with an erythematous patch that blisters centrally, erodes, and then crusts over and heals with hyperpigmentation
    • The lesions are typically annular or polycyclic and may become confluent
       
  • Other features
    • May include glossitis and dry, cracked lips

Images

Please click on images to enlarge, or choose to download. Images must only be used for teaching purposes and are not for commercial use. Notice and credit must be given to the PCDS and any other named contributor.

Download

Figure: 1

Necrolytic migratory erythema

Download

Figure: 2

Necrolytic migratory erythema

Download

Figure: 3

Necrolytic migratory erythema

Download

Figure: 4

Necrolytic migratory erythema


Investigations

  • Blood tests
    • May reveal diabetes mellitus, anaemia, and deranged LFTs if there is liver involvement 
    • Serum glucagon levels may be very raised
       
  • Skin biopsy
    • Histology may reveal inflammation and separation of the superficial layers of the epidermis
       
  • Once a diagnosis has been made further blood tests are required to look for evidence of a multiple endocrine neoplasia syndrome, as well as imaging studies to identify the source of the glucagonoma

Management

  • NME usually resolves once the glucagonoma has been surgically removed. However, if the tumour has already spread to other organs such as the liver, surgery is not as effective
  • Chemotherapy may help some patients
  • Unfortunately, about 50% of patients die within five years of diagnosis

  • PCDS Corporate Sponsors (View all sponsors)
  • Contact Us
  • Site Map
  • Disclaimer

Copyright © 1994 - 2017 The Primary Care Dermatology Society. All rights reserved. Charity No. 1109376
Lead Author - Dr Tim Cunliffe. Web Design - Mode Ten Designs.


2nd Floor, Titan Court, 3 Bishop Square, Hatfield, AL10 9NA. UK
Tel: 01707 226024 Email: pcds@pcds.org.uk

PCDS Latest News & Bulletins

PCDS Bulletin Summer 2017  |  06.06.2017
PCDS Bulletin Winter 2016  |  30.11.2016
PCDS Bulletin Summer 2016  |  13.06.2016